What a mechanism claim can and cannot predict

The most common sentence in this market

Almost every peptide sold today is sold on a pathway. It binds a receptor. It signals a gland. It mimics a fragment of something the body already makes.

Those sentences are often true. They are also a different kind of claim from the one a buyer is actually making a decision about, which is whether taking it changes anything they would notice.

The gap between those two claims has a name in regulation and a long history in medicine. Knowing where the seam is turns a persuasive product page back into a set of separate questions.

A drug label keeps them in different sections

The clearest evidence that these are two different things is that federal labeling rules separate them, by number.

Section 12 of a prescription drug label is Clinical Pharmacology. Its first subsection, 12.1, is Mechanism of action. The regulation says that subsection must summarize what is known about the established mechanisms of the drug's action in humans, at levels such as receptor, membrane, tissue, organ and whole body.

Section 14 is Clinical Studies. That is where the trials go.

A pathway and a result sit in different numbered places on the same document, because they answer different questions and can be true independently of each other.

The regulation allows the mechanism to be unknown

The same rule contains a sentence that settles the whole argument. If the mechanism of action is not known, the subsection must contain a statement about the lack of information.

Read that literally. A medicine can be approved, marketed and prescribed while its label openly says nobody is sure how it works.

That is only possible because the approval rests on section 14, not section 12. Effectiveness is established by studying what happened to people, and an unexplained effect that reliably shows up is still an effect.

The reverse follows, and it is the part product pages leave out. If a known mechanism is not required for approval, a known mechanism cannot be what proves a benefit.

A mechanism adds weight to a finding it does not replace

None of this makes a pathway worthless, and the federal advertising standard is precise about its role.

The Federal Trade Commission's guidance for health product marketers lists what strengthens a body of research. Among the things that add weight to research findings, it names evidence of a dose-response relationship and a recognized biological or chemical mechanism to explain the effect.

The grammar of that sentence is the point. A mechanism adds weight to findings. It is not one of them.

So the honest version of a mechanism claim is a hypothesis with a reason behind it. That is genuinely better than a hypothesis with no reason behind it, and it is not a substitute for the study.

The trial that ended the argument

Medicine learned this the expensive way, and the case is worth knowing because the reasoning was so reasonable.

People who survive a heart attack often have extra, irregular heartbeats, and people with more of them die more often. Drugs existed that reliably reduced those extra beats. The inference was obvious: suppress the beats, prevent the deaths.

The Cardiac Arrhythmia Suppression Trial was designed to test exactly that hypothesis. Patients whose irregular beats could be suppressed were randomly assigned to the active drug or to a placebo.

Two of the drugs were stopped early because of excess deaths. Among roughly fifteen hundred patients followed for a mean of ten months, fifty-nine died of arrhythmia, forty-three of them on the drug and sixteen on placebo.

The drugs did what the mechanism said. The extra beats went down. More people died anyway.

The authors' closing line is the sentence to keep. The mechanisms underlying the excess mortality during treatment remain unknown.

Why a plausible pathway fails so often

A mechanism claim is a prediction about one pathway in a system with many. It is right about the pathway and silent about everything else the molecule touches.

It is also silent about size. A receptor that responds says nothing about whether the response is large enough for a person to notice.

It is silent about duration. A signal measured over hours predicts nothing about months.

And it is silent about the balance. Almost every intervention does several things at once, and only a trial counts the good and the bad in the same population over the same period.

Those four silences are why the pathway can be exactly right and the product still useless, or worse.

Where mechanism claims come from in this market

Most compounds sold as peptide therapy have a mechanism story and no controlled human trial of the marketed use. The story is usually the strongest thing available, so it does most of the selling.

Regulatory reviews of these compounds keep landing on the same finding. For one peptide evaluated by the agency, reviewers concluded that the receptors the marketing story depends on are unlikely to be the molecular targets behind the reported effects. Other pathways have been proposed, and none is established.

For another, the review recorded that dose-response relationships had not been established, that molecular targets had not been identified, and that the mechanisms remain poorly understood.

A mechanism that is itself unverified is a weaker thing again. It is a hypothesis about a hypothesis.

How to read a pathway claim on a product page

Separate the two sentences. One says what the compound is thought to do inside the body. The other says what happened to people who took it. Find both, or notice that only one is there.

Ask whether the mechanism is established or proposed. Established means measured in humans and generally accepted. Proposed means someone has an idea.

Ask what the mechanism predicts, specifically. A vague pathway predicts nothing testable, and a specific one is a reason to look for the test.

Then look for the test. A pathway that has been known for twenty years with no controlled trial behind it is telling you something about how hard the trial would be to win.

Two compounds on this site are approved drugs whose labels carry both sections, semaglutide and tirzepatide. For the rest, section 14 has nothing in it, because the trials have not been run and published.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 201.57 — Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1) — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
2. Health Products Compliance Guidance — U.S. Federal Trade Commission, December 2022
3. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial — The New England Journal of Medicine, volume 324, pages 781-788 (PubMed identifier 1900101), March 1991
4. Step 2: Preclinical Research — U.S. Food and Drug Administration, January 2018